UK based drug delivery specialist, Q Chip, launches ocular spin-out, OpsiRx Pharmaceuticals, reports significant progress and appoints new Chairman

Q Chip's Board made the following announcement today:

·         Q Chip has launched OpsiRx Pharmaceuticals Ltd ("OpsiRx"), the ophthalmology company developing products addressing unmet clinical needs including in uveitis and glaucoma. 

·         The Company has successfully demonstrated sterile manufacturing for its proprietary technology. Achievement of this milestone now enables production of material for clinical studies. The Independent clinical advisory board to OpsiRx has identified sustained release delivery direct to the eye as the ideal application.

·         The company is also pleased to announce that Simon Turton has joined as Chairman. Formerly Head of European Healthcare Investments at Warburg Pincus, Dr Turton brings a wealth of experience in pharmaceuticals including in ophthalmology.

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.